Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts remain bullish: Ligand Pharmaceuticals has a “Moderate Buy” consensus from eight analysts, with seven buy ratings and an average 12-month price target of approximately $336.57.
• Quarterly results beat expectations: Adjusted EPS came in at $2.37 versus the roughly $1.97 consensus, while revenue reached $63.69 million, up 33.8% year over year. The company raised fiscal 2026 adjusted EPS guidance to $9.00–$9.50 but reaffirmed revenue guidance of $270–$310 million.
• Shares have pulled back despite favorable results: LGND opened at $293.15, down 2.3%, following its earnings report. Recent insider selling and revenue guidance that fell short of the consensus midpoint may have weighed on investor sentiment.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $336.5714.

A number of research analysts have issued reports on LGND shares. Weiss Ratings cut Ligand Pharmaceuticals from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. Citigroup initiated coverage on Ligand Pharmaceuticals in a report on Tuesday, July 21st. They set a "buy" rating and a $387.00 price objective on the stock. Stifel Nicolaus boosted their price objective on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Bank of America increased their target price on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the stock a "buy" rating in a research note on Thursday, July 9th. Finally, Oppenheimer restated an "outperform" rating and set a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd.

Ligand Pharmaceuticals Trading Down 2.3%

Shares of NASDAQ LGND opened at $293.15 on Friday. Ligand Pharmaceuticals has a twelve month low of $137.14 and a twelve month high of $326.63. The stock has a market cap of $5.87 billion, a price-to-earnings ratio of 31.35, a P/E/G ratio of 2.71 and a beta of 1.13. The company has a quick ratio of 20.95, a current ratio of 34.52 and a debt-to-equity ratio of 1.16. The company's fifty day moving average is $285.97 and its 200-day moving average is $235.30.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $1.97 by $0.40. The business had revenue of $63.69 million during the quarter, compared to analysts' expectations of $61.30 million. Ligand Pharmaceuticals had a net margin of 67.88% and a return on equity of 20.06%. The firm's quarterly revenue was up 33.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.60 EPS. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Equities research analysts predict that Ligand Pharmaceuticals will post 4.89 EPS for the current year.

Key Headlines Impacting Ligand Pharmaceuticals

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Ligand reported second-quarter adjusted EPS of $2.37, beating analysts’ $1.95 consensus estimate, while revenue of $63.69 million exceeded expectations of $60.87 million. Revenue increased 33.8% year over year, and EPS rose from $1.60 in the prior-year quarter. Ligand Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS outlook to $9.00-$9.50, above the $8.13 analyst consensus. The outlook implies continued earnings growth and supports the investment case for Ligand’s royalty-focused business model. Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed
• Positive Sentiment: Royal Bank of Canada raised its price target from $340 to $345 and maintained an “outperform” rating. HC Wainwright also lifted its target from $289 to $358 and assigned a “buy” rating, signaling that analysts see further upside. Analyst Price Target Updates
• Neutral Sentiment: Ligand reaffirmed fiscal 2026 revenue guidance of $270 million-$310 million. Although the midpoint is below the $287.5 million consensus estimate, the range remains consistent with the company’s previous outlook and may reflect the timing of royalty and licensing revenue. Ligand Pharmaceuticals 2026 Q2 Results Presentation
• Negative Sentiment: The stock’s decline following the earnings beat suggests investors may have been looking for a larger revenue outlook increase or may be locking in gains after the shares’ strong run. The mixed revenue guidance could be limiting the immediate reaction to the otherwise favorable results. Biopharma Royalty Powerhouse Dips Despite Beat-and-Raise Quarter

Insider Buying and Selling

In related news, Director Jason Haas sold 6,461 shares of the business's stock in a transaction on Friday, June 12th. The shares were sold at an average price of $255.58, for a total value of $1,651,302.38. Following the sale, the director directly owned 4,981 shares of the company's stock, valued at approximately $1,273,043.98. The trade was a 56.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jason Aryeh sold 4,500 shares of the company's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $250.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the director directly owned 102,580 shares of the company's stock, valued at approximately $25,645,000. The trade was a 4.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 35,231 shares of company stock valued at $9,199,401. 5.60% of the stock is owned by corporate insiders.

Institutional Trading of Ligand Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC lifted its holdings in shares of Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 69 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Ligand Pharmaceuticals during the fourth quarter worth about $31,000. JPL Wealth Management LLC bought a new position in shares of Ligand Pharmaceuticals during the third quarter worth about $52,000. Covestor Ltd grew its holdings in shares of Ligand Pharmaceuticals by 17,050.0% during the fourth quarter. Covestor Ltd now owns 343 shares of the biotechnology company's stock worth $65,000 after buying an additional 341 shares in the last quarter. Finally, IFP Advisors Inc raised its position in Ligand Pharmaceuticals by 1,040.0% in the 4th quarter. IFP Advisors Inc now owns 342 shares of the biotechnology company's stock valued at $65,000 after buying an additional 312 shares during the last quarter. Institutional investors and hedge funds own 91.28% of the company's stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company's product offerings center around several core platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source